ELOVL1 anticorps

N° du produit ABIN2423375

Détail du produit anti-ELOVL1 anticorps

Antigène: ELOVL1 (ELOVL Fatty Acid Elongase 1 (ELOVL1))

Reactivité: Humain, Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp ELOVL1 est non-conjugé

Application: ELISA, Immunohistochemistry (IHC)

Purification: Affinity purification

Immunogène: Recombinant protein of human ELOVL1

Isotype: IgG

Information d'application

Indications d'application: IHC 1:50-1:200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.6 mg/mL

Buffer: PBS with 0.05 % sodium azide and 50 % glycerol, PH7.4

Agent conservateur: Sodium azide

Conseil sur la manipulation: Avoid freeze / thaw cycles.

Stock: -20 °C

Stockage commentaire: Store at -20°C. Avoid freeze / thaw cycles.

Détails sur ELOVL1

Antigène: ELOVL1 (ELOVL Fatty Acid Elongase 1 (ELOVL1))

Autre désignation: ELOVL1 (ELOVL1 Produits)

Synonymes: anticorps AA407424, anticorps BB151133, anticorps Ssc1, anticorps elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 1, anticorps ELOVL fatty acid elongase 1, anticorps Elovl1, anticorps ELOVL1

Sujet: Elongation of very long chain fatty acid-like (ELOVL) proteins 1-6 are members of the ELO family of proteins, which play an important role in tissue-specific biosynthesis of very long chain fatty acids and sphingolipids. The ELOVL proteins act as catalysts in fatty acid elongation reduction and localize to the endoplasmic reticulum (ER). Elongation of very long chain fatty acids protein 1 (ELOVL1), also referred to as Ssc1, is the human homolog of the yeast ELO3 protein. It is expressed in a variety of tissues and at especially high levels in stomach, skin, intestine, kidney and lung. ELOVL1 participates in the elongation of very long chain saturated and monounsaturated fatty acids of up to 26 carbons and may be required for the development of a barrier in epithelial cells and skin. ELOVL1 is also important for the formation of Myelin in the central nervous system. Impaired ELOVL1 activity may be associated with disorders of sphingolipid metabolism.